Diao H

No ORCID on file · 8 papers in corpus · active 2021-2025
2025
Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov.
Frontiers in medicine ·doi:10.3389/fmed.2025.1521587

Antibodies have been widely used globally over the past decade and play an increasingly important role in modern medicine. Notably, significant advancements have been achieved in the realm of gynecology, particularly in gynecological cancer…

2025
Serum concentrations of medroxyprogesterone acetate were undetectable on OPU+5 days and had no effect on the serum progesterone level in patients undergoing the progestin-primed ovarian stimulation protocol.
Frontiers in endocrinology ·doi:10.3389/fendo.2025.1490839

ObjectiveTo evaluate the dynamics of serum medroxyprogesterone acetate (MPA) concentrations and their influence on serum progesterone (P) levels and pregnancy outcomes in the progestin-primed ovarian stimulation (PPOS) protocol. A total of …

2025
The Follicular Output Rate was Improved with 3-Day Letrozole Administration Compared with 5-Day Letrozole Administration Under Progestin-Primed Ovarian Stimulation.
Drug design, development and therapy ·doi:10.2147/dddt.s521554

PurposeProgestin-primed ovarian stimulation (PPOS) has been widely employed in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. In recent years, letrozole (LE) combined with medroxyprogesterone acetate (MPA) has be…

2025
The study on the clinical efficacy of endometrial receptivity analysis and influence factors of displaced window of implantation.
Scientific reports ·doi:10.1038/s41598-025-91745-y

The endometrial receptive status is critical for a successful embryo implantation, but it only last for a short period of time, and the window of implantation (WOI) of each woman changes individually, which will lead to poor outcomes of ass…

2023
The comparison between fixed versus degressive doses of medroxyprogesterone acetate combined with letrozole in patients of progestin-primed ovarian stimulation protocol: a propensity score-matched study.
Frontiers in endocrinology ·doi:10.3389/fendo.2023.1295787

ObjectiveTo explore the cycle characteristics and pregnancy outcomes of progestin-primed ovarian stimulation (PPOS) using fixed versus degressive doses of medroxyprogesterone acetate (MPA) in conjunction with letrozole (LE) in infertile wom…

2023
The serum oestradiol/progesterone ratio on the day of OPU + 7, but not the day of OPU + 5, affects the rates of live birth in fresh blastocyst embryo transfer cycles.
Journal of ovarian research ·doi:10.1186/s13048-023-01096-3

BackgroundIn an in vitro fertilization (IVF) cycle, the embryo ends its wandering time and begins the process of implantation into the uterine cavity on the seventh day after oocyte pick-up (OPU + 7), which is closer than OPU + 5 to the tim…

2022
The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study.
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-022-01014-0

BackgroundThe gonadotropin-releasing hormone agonist (GnRH-a) has been used in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles for a long time. This paper evaluates the efficacy and safety of two commonly used prot…

2021
TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer.
International journal of molecular sciences ·doi:10.3390/ijms23010250

We have previously found that TdT-interacting factor 1 (TdIF1) is a potential oncogene expressed in non-small cell lung cancer (NSCLC) and is associated with poor prognosis. However, its exact mechanism is still unclear. The lysine-specific…